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Editorial 
Smoking cessation: professional problem or public 
policy? 
Smoking-related lung diseases form the major part 
of respiratory physicians’ workload in the developed 
world. The evidence for the association of cigarettes 
and lung disease remains compelling (1,2) and gains 
further support from the most recent follow-up study 
reported by Sir Richard Doll and his colleagues (3). 
They found that smokers aged 45-64 years had a 
three-fold excess mortality compared with non- 
smokers, and those aged 65-84 years had doubling of 
their mortality. Their data clearly demonstrates the 
well-known dose-response relationship between the 
number of cigarettes smoked and the likelihood of 
dying from major pulmonary disease. Thus the 
mortality rate for all respiratory diseases is 4.7 times 
higher in people smoking more than 25 cigarettes 
day- i than in non-smokers, and that from lung 
cancer and chronic obstructive pulmonary disease 
(COPD) are 2.5 and 23 times greater, respectively, in 
similarly heavy smokers (3). If smoking habits con- 
tinue unchanged, excess annual mortality due to 
tobacco will increase from 2 to 3 million by 2025 in 
the developed world and from 1 to 7 million in the 
developing world (4). 
Smoking cessation is worthwhile and the sooner 
the better, although statistically significant improve- 
ments in expected mortality can be seen even when 
the patients stop smoking in later life (3). Similar 
findings are seen when other indices of cigarette- 
induced lung damage such as the rate of decline in 
FEV, are studied (5,6). Other indirect gains from 
stopping smoking, apart from the financial ones, 
are a reduction in passive-smoking-induced lung 
tumours and in childhood respiratory diseases, par- 
ticularly asthma, where there is a strong association 
between parental smoking and disease development 
particularly when the mother smokes during 
pregnancy (7,8). 
If awareness of the risks of smoking was all that 
was needed to discourage it, then smoking cessation 
would be a simple task. In one sense this is true, at 
least among those who understand what the evidence 
really means, as the number of British doctors smok- 
ing cigarettes has fallen from 53% 40 years ago to 7% 
now. However, nicotine is a drug of addiction and 
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cigarettes are a particularly effective way of delivering 
it. The alkaline pH of manufactured cigarettes 
encourages nicotine absorption from the alveoli with 
the drug reaching the brain within 10 s (9). This gives 
exquisite control of the dose of nicotine delivered 
which can be varied by minor changes in puff volume 
and inspiratory flow rate to ensure a constant level in 
the blood (10). We should not be surprised then that 
nicotine is rated a harder drug to abandon than is 
cocaine among those addicted to both (11). However, 
physical dependence is not the only, or even neces- 
sarily the greatest, barrier to smoking cessation. For 
many patients, smoking defines their social identity 
from youth when they use it as a marker of adult 
behaviour, through middle age when the exchange of 
cigarettes and shared smoking promotes social bond- 
ing through to the point when fears of imminent 
mortality, real or imagined, make them stop. The 
skilful marketing of cigarettes as social statements 
has prevented a rapid collapse of tobacco sales in the 
face of medical evidence of its dangers. Thus atten- 
tion to both the individual patients need and the 
wider social context of their tobacco use is needed if 
smoking cessation rates are to rise. 
Abundant data are available about the impact of 
doctor advice on smokers. Brief anti-smoking advice 
from a family physician will persuade 3.5% of 
patients to stop smoking permanently rising to 5.5% 
if the advice is accompanied by anti-smoking litera- 
ture (12). Rather better results of 5.1% and 8.1% 
sustained quitting are seen when respiratory out- 
patients are advised in a similar fashion at the 
hospital outpatient clinic (13). If patients are 
more positively motivated and smoke more than 10 
cigarettes day ~ i, prescription of nicotine replace- 
ment as either gum or transcutaneous patches can 
double their quit rates with sustained abstinence of 
up to 23% in some series of smokers attending 
specific clinics and about half this rate in general 
community use (14,15). The use of nicotine gum 
appears to be more acceptable in studies from North 
America compared with Europe. 
The most recent study to address this issue is the 
Lung Health Study of smokers with early chronic 
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obstructive pulmonary disease (16). In this 5-yr trial, 
5887 smokers, mean age 48.5 years with spirometric 
evidence of COPD (mean FEV, 2.64 1, mean FEV,/ 
FVC ratio 63%) were randomized to either normal 
advice as above or an intensive smoking cessation 
programme including nicotine gum with or without 
the addition of inhaled ipratropium bromide. The 
rate of decline of FEV, with time did not differ 
between patients treated with the anti-cholinergic 
drug or placebo but was significantly less in those 
given gum and advice than in patients just given 
normal anti-smoking advice (196 ml vs. 267 ml 
respectively). The intensive advice groups who used 
nicotine gum up to and beyond 12 months had a 
higher sustained quit rate than did the control group 
(22% vs. 5%). Thus in patients willing to consider 
stopping smoking, intensive advice and nicotine 
replacement can be effective. Foulds and Jarvis have 
suggested that a combination of brief advice for all, 
and intensive follow-up for patients interested, would 
persuade about 6% of all smokers to stop perma- 
nently, offering them a doubling of life expectancy 
over the subsequent 15 yr (17). 
Such strategies are important for individual 
smokers and produce a significant health gain since 
even these modest results are important given the 
continuing high prevalence of smoking. However, 
larger impacts on smoking which will actually pre- 
vent disease must rely on central government action 
which is likely to offend vested tobacco interests. 
Public health education campaigns to reduce smok- 
ing have been effective (18). Thus the present level of 
cigarette consumption is not only lower in absolute 
terms than that in the 1960s but represents a reversal 
of the previously remorseless increase in tobacco 
sales that had begun in the 1930s. The most effective 
means of reducing cigarette sales are the restriction of 
tobacco advertising and increasing product cost ‘in 
real terms’. Powerful evidence for the former comes 
from New Zealand where tobacco sales fell by 9.6% 
in the first 2 yr after legislation banning tobacco 
advertising with a projected reduction in smoking 
prevalence of 15% of the population by the end of the 
century. At least one authoritative overview has 
supported the importance of this step (19). Failure to 
ban tobacco advertising says more about political 
expediency than the quality of the data against it. 
Targeting of advertising to specific groups is a recent, 
more sinister, development well documented in devel- 
oping countries, but also seen in the developed world. 
There are now clear data showing that the introduc- 
tion in the U.K. of a poster campaign using the 
‘cheeky chappy’ character Reg to promote Embassy 
Regal cigarettes led to an increase in the number of 
cigarettes smoked, and an increased smoking preva- 
lence among children in those areas of the U.K. 
exposed to the campaign compared with those not so 
targeted (20). These data discredit the often repeated 
claim that advertising does not increase sales but 
simply serves to reinforce brand identity. 
Tobacco sales show significant price sensitivity 
such that a 1% increase in price will reduce overall 
sales by 0.5% (21). Recent moves to increase tobacco 
taxation in a planned fashion beyond the rate of 
inflation must be welcomed (22). However, there are 
significant differences in the impact of health public- 
ity and taxation between men and women and in 
different socio-economic groups. People in lower 
socio-economic groups smoke significantly more 
(50% of poor unemployed people smoke compared 
with 16% of professionals) and these groups show 
significant price sensitivity reducing their smoking by 
1% for each 1% increase in price, unlike more affluent 
smokers who are unaffected by this. Women of all 
ages, including teenagers, are less responsive to 
health publicity but are more responsive to changes 
in cigarette price (21). In general, the impact of health 
publicity declines significantly with age. Thus any 
solution to the problem of smoking must address 
these facts which are supported by evidence from 
many other countries. Without positive leadership 
from central government and a willingness to take an 
unpopular decision on taxation, sustained tobacco 
abstinence will not be possible. 
Important though taxation, health publicity and 
advertising restrictions are, these steps alone will not 
be enough to eradicate smoking. The creation of 
smoke-free environments in public places, govern- 
ment offices and recreational areas coupled with legal 
action against people breaking such restrictions 
which lead to the encouragement of a ‘smoke-free’ 
culture are essential if the social use of tobacco is to 
be curbed. Outright prohibition as has been 
attempted with alcohol is not likely to produce 
sustained behavioural changes and may create a 
ghetto mentality among persecuted smokers. 
For respiratory physicians, tobacco smoking has 
produced a ‘smoky grey’ plague to replace the white 
plague of tuberculosis that dominated our clinical 
lives until the middle of the century. The resolution 
of the TB epidemic came gradually with better 
nutrition, housing and legislation to encourage case 
finding and immunization. Chemotherapy made an 
enormous difference to the individual patient and 
contributed somewhat to the overall decline in dis- 
ease prevalence (23). I believe the same to be true for 
the smoking-related lung diseases. As physicians, it is 
vital that we support national efforts to increase 
Editorial 125 
tobacco taxation, ban tobacco advertising and 
encourage a smoke-free culture whilst ensuring that 
sufficient time and resources are available to help the 
individual patient stop smoking. These goals are not 
incompatible nor must they be made to appear so. 
P. M. A. CALVERLEY 
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